Patients’ Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing

Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics

(2017) Maira Kentwell et al.   GYNECOLOGIC ONCOLOGY

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

(2017) Karoline B. Kuchenbaecker et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access

(2017) Hannah Shipman et al.   Journal of Genetic Counseling

Rapid genetic counseling and testing in newly diagnosed breast cancer: Patients’ and health professionals’ attitudes, experiences, and evaluation of effects on treatment decision making

(2017) Marijke R. Wevers et al.   JOURNAL OF SURGICAL ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

(2017) Saeed Rafii et al.   Oncotarget

Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer

(2016) Akiko Chiba et al.   ANNALS OF SURGICAL ONCOLOGY

When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer

(2016) B Meiser et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial

(2016) Veronica F. Quinn et al.   GENETICS IN MEDICINE

Identifying Needs: a Qualitative Study of women’s Experiences Regarding Rapid Genetic Testing for Hereditary Breast and Ovarian Cancer in the DNA BONus Study

(2016) Mirjam Tonheim Augestad et al.   Journal of Genetic Counseling

Therapeutic appropriation: a new concept in the ethics of clinical research

(2016) Rosalind McDougall et al.   JOURNAL OF MEDICAL ETHICS

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

(2016) Angela George et al.   Nature Reviews Clinical Oncology

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study

(2015) Hildegunn Høberg-Vetti et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study

(2015) M. R. Wevers et al.   Familial Cancer

Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial

(2015) Marijke R. Wevers et al.   GENETICS IN MEDICINE

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

(2015) Melinda L. Telli et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of cancer genetic services in the UK: A national consultation

(2015) Ingrid Slade et al.   Genome Medicine

Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer

(2014) Francisco J. Candido-dos-Reis et al.   CLINICAL CANCER RESEARCH

Mainstreaming genetic testing of cancer predisposition genes

(2014) N. Rahman   CLINICAL MEDICINE

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

(2012) Kathryn Alsop et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breast cancer genetic counseling after diagnosis but before treatment: A pilot study on treatment consequences and psychological impact

(2012) Marijke R. Wevers et al.   PATIENT EDUCATION AND COUNSELING

Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer

(2012) E. Zilliacus et al.   SUPPORTIVE CARE IN CANCER

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

(2011) Shiyu Zhang et al.   GYNECOLOGIC ONCOLOGY

There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer

(2011) B. Meiser et al.   GYNECOLOGIC ONCOLOGY

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of BRCA mutation testing in determining breast cancer therapy

(2010) Alison H. Trainer et al.   Nature Reviews Clinical Oncology

The Effect of BRCA Gene Testing on Family Relationships: A Thematic Analysis of Qualitative Interviews

(2009) Heather A. Douglas et al.   Journal of Genetic Counseling

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

(2008) David S.P. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY